Correlation between bone metabolic markers and bone scan in prostatic cancer

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 539-543

  Maeda, Hiroshi ^a,b   Koizumi, Mitsuru ^a   Yoshimura, Koji ^a   Yamauchi, Tamio ^a   Kawai, Tsuneo ^a   Ogata, Etsuro ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

biological; neoplasm metastasis; prostate specific antigen; prostatic neoplasms; tumor markers

Indexed keywords

OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031021526     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65196-6     Document Type: Article

References (16)

1. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
2. Miller, P. D., Eardley, I. and Kirby, R. S.: Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Brit. J. Urol., 70: 295, 1992.
3. Cooper, E. H., Whelan, P. and Purves, D.: Bone alkaline phosphatase and prostate-specific antigen in monitoring of prostate cancer. Prostate, 25: 236, 1994.
4. Eyre, D. R., Koob, T. J. and Van Ness, K. P.: Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal. Biochem., 137: 380, 1984.
5. Coleman, R. E., Houston, S., James, I., Rodger, A., Rubens, R. D., Leonard, R. C. and Ford, J.: Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Brit. J. Cancer, 65: 766, 1992.
6. Risteli, J., Elomaa, I., Niemi, S., Novamo, A. and Risteli, L.: Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem., 39: 635, 1993.
7. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S. and Moinuddin, M.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61: 195, 1988.
8. Catalona, W. J. and Scott, W. W.: Carcinoma of the prostate. In: Campbell's Urology, 5th ed. Edited by P. C. Walsh, R. F. Gittes, A. D. Perlmutter and T. A. Stamey. Philadelphia: W. B. Saunders Co., vol. 2, chapt. 32, pp. 1463-1534, 1986.
9. Koizumi, M., Yamada, Y., Takiguchi, T., Nomura, E., Furukawa, M., Kitahara, T., Yamashita, T., Maeda, H., Takahashi, S., Aiba, K. and Ogata, E.: Bone metabolic markers in bone metastases. J. Cancer Res. Clin. Oncol., 121: 542, 1995.
10. Robins, S. P., Woitge, H., Hesley, R., Ju, J., Seyedin, S. and Seibel, M. J.: Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Min. Res., 9: 1643, 1994.
11. Gomez, B., Jr., Ardakani, S., Ju, J., Jenkins, D., Cerelli, M. J., Daniloff, G. Y. and Kung V. T.: Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin. Chem., 41: 1560, 1995.
12. Pollen, J. J., Witztum, K. F. and Ashburn, W. L.: The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR, 142: 773, 1984.
13. Kylmala, T., Tammela, T. L. J., Risteli, L., Risteli, J., Kontturi, M. and Elomaa, I.: Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Brit. J. Cancer, 71: 1061, 1995.
14. Clarke, N. W., McClure, J. and George, N. J.: Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Brit. J. Urol., 69: 64, 1992.
15. Elomaa, I., Virkkunen, P., Risteli, L. and Risteli, J.: Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Brit. J. Cancer, 66: 337, 1992.
16. Leo, M. E., Bilhartz, D. L., Bergstralh, E. J. and Oesterling, J. E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J. Urol., 145: 802, 1991.